Cargando…

Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial

BACKGROUND: Soft-tissue sarcomas (STS) represent a heterogeneous group of rare tumors including more than 70 different histological subtypes. High throughput molecular analysis (next generation sequencing exome [NGS]) is a unique opportunity to identify driver mutations that can change the usual one...

Descripción completa

Detalles Bibliográficos
Autores principales: Italiano, Antoine, Dinart, Derek, Soubeyran, Isabelle, Bellera, Carine, Espérou, Hélène, Delmas, Christelle, Mercier, Noémie, Albert, Sabrina, Poignie, Ludivine, Boland, Anne, Bourdon, Aurélien, Geneste, Damien, Cavaille, Quentin, Laizet, Yec’han, Khalifa, Emmanuel, Auzanneau, Céline, Squiban, Barbara, Truffaux, Nathalène, Olaso, Robert, Gerber, Zuzana, Wallet, Cédrick, Bénard, Antoine, Blay, Jean-Yves, Laurent-Puig, Pierre, Deleuze, Jean-François, Lucchesi, Carlo, Mathoulin-Pelissier, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570026/
https://www.ncbi.nlm.nih.gov/pubmed/34740331
http://dx.doi.org/10.1186/s12885-021-08878-2
_version_ 1784594760172830720
author Italiano, Antoine
Dinart, Derek
Soubeyran, Isabelle
Bellera, Carine
Espérou, Hélène
Delmas, Christelle
Mercier, Noémie
Albert, Sabrina
Poignie, Ludivine
Boland, Anne
Bourdon, Aurélien
Geneste, Damien
Cavaille, Quentin
Laizet, Yec’han
Khalifa, Emmanuel
Auzanneau, Céline
Squiban, Barbara
Truffaux, Nathalène
Olaso, Robert
Gerber, Zuzana
Wallet, Cédrick
Bénard, Antoine
Blay, Jean-Yves
Laurent-Puig, Pierre
Deleuze, Jean-François
Lucchesi, Carlo
Mathoulin-Pelissier, Simone
author_facet Italiano, Antoine
Dinart, Derek
Soubeyran, Isabelle
Bellera, Carine
Espérou, Hélène
Delmas, Christelle
Mercier, Noémie
Albert, Sabrina
Poignie, Ludivine
Boland, Anne
Bourdon, Aurélien
Geneste, Damien
Cavaille, Quentin
Laizet, Yec’han
Khalifa, Emmanuel
Auzanneau, Céline
Squiban, Barbara
Truffaux, Nathalène
Olaso, Robert
Gerber, Zuzana
Wallet, Cédrick
Bénard, Antoine
Blay, Jean-Yves
Laurent-Puig, Pierre
Deleuze, Jean-François
Lucchesi, Carlo
Mathoulin-Pelissier, Simone
author_sort Italiano, Antoine
collection PubMed
description BACKGROUND: Soft-tissue sarcomas (STS) represent a heterogeneous group of rare tumors including more than 70 different histological subtypes. High throughput molecular analysis (next generation sequencing exome [NGS]) is a unique opportunity to identify driver mutations that can change the usual one-size-fits-all treatment paradigm to a patient-driven therapeutic strategy. The primary objective of the MULTISARC trial is to assess whether NGS can be conducted for a large proportion of metastatic STS participants within a reasonable time, and, secondarily to determine whether a NGS-guided therapeutic strategy improves participant’s outcome. METHODS: This is a randomized, multicentre, phase II/III trial inspired by the design of umbrella and biomarker-driven trials. The setting plans up to 17 investigational centres across France and the recruitment of 960 participants. Participants aged at least 18 years, with unresectable locally advanced and/or metastatic STS confirmed by the French sarcoma pathological reference network, are randomized according to 1:1 allocation ratio between the experimental arm “NGS” and the standard “No NGS”. NGS will be considered feasible if (i) NGS results are available and interpretable, and (ii) a report of exome sequencing including a clinical recommendation from a multidisciplinary tumor board is provided to investigators within 7 weeks from reception of the samples on the biopathological platform. A feasibility rate of more than 70% is expected (null hypothesis: 70% versus alternative hypothesis: 80%). In terms of care, participants randomized in “No NGS” arm and who fail treatment will be able to switch to the NGS arm at the request of the investigator. DISCUSSION: The MULTISARC trial is a prospective study designed to provide high-level evidence to support the implementation of NGS in routine clinical practice for advanced STS participants, on a large scale. TRIAL REGISTRATION: clinicaltrial.gov NCT03784014. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08878-2.
format Online
Article
Text
id pubmed-8570026
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85700262021-11-08 Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial Italiano, Antoine Dinart, Derek Soubeyran, Isabelle Bellera, Carine Espérou, Hélène Delmas, Christelle Mercier, Noémie Albert, Sabrina Poignie, Ludivine Boland, Anne Bourdon, Aurélien Geneste, Damien Cavaille, Quentin Laizet, Yec’han Khalifa, Emmanuel Auzanneau, Céline Squiban, Barbara Truffaux, Nathalène Olaso, Robert Gerber, Zuzana Wallet, Cédrick Bénard, Antoine Blay, Jean-Yves Laurent-Puig, Pierre Deleuze, Jean-François Lucchesi, Carlo Mathoulin-Pelissier, Simone BMC Cancer Study Protocol BACKGROUND: Soft-tissue sarcomas (STS) represent a heterogeneous group of rare tumors including more than 70 different histological subtypes. High throughput molecular analysis (next generation sequencing exome [NGS]) is a unique opportunity to identify driver mutations that can change the usual one-size-fits-all treatment paradigm to a patient-driven therapeutic strategy. The primary objective of the MULTISARC trial is to assess whether NGS can be conducted for a large proportion of metastatic STS participants within a reasonable time, and, secondarily to determine whether a NGS-guided therapeutic strategy improves participant’s outcome. METHODS: This is a randomized, multicentre, phase II/III trial inspired by the design of umbrella and biomarker-driven trials. The setting plans up to 17 investigational centres across France and the recruitment of 960 participants. Participants aged at least 18 years, with unresectable locally advanced and/or metastatic STS confirmed by the French sarcoma pathological reference network, are randomized according to 1:1 allocation ratio between the experimental arm “NGS” and the standard “No NGS”. NGS will be considered feasible if (i) NGS results are available and interpretable, and (ii) a report of exome sequencing including a clinical recommendation from a multidisciplinary tumor board is provided to investigators within 7 weeks from reception of the samples on the biopathological platform. A feasibility rate of more than 70% is expected (null hypothesis: 70% versus alternative hypothesis: 80%). In terms of care, participants randomized in “No NGS” arm and who fail treatment will be able to switch to the NGS arm at the request of the investigator. DISCUSSION: The MULTISARC trial is a prospective study designed to provide high-level evidence to support the implementation of NGS in routine clinical practice for advanced STS participants, on a large scale. TRIAL REGISTRATION: clinicaltrial.gov NCT03784014. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08878-2. BioMed Central 2021-11-05 /pmc/articles/PMC8570026/ /pubmed/34740331 http://dx.doi.org/10.1186/s12885-021-08878-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Italiano, Antoine
Dinart, Derek
Soubeyran, Isabelle
Bellera, Carine
Espérou, Hélène
Delmas, Christelle
Mercier, Noémie
Albert, Sabrina
Poignie, Ludivine
Boland, Anne
Bourdon, Aurélien
Geneste, Damien
Cavaille, Quentin
Laizet, Yec’han
Khalifa, Emmanuel
Auzanneau, Céline
Squiban, Barbara
Truffaux, Nathalène
Olaso, Robert
Gerber, Zuzana
Wallet, Cédrick
Bénard, Antoine
Blay, Jean-Yves
Laurent-Puig, Pierre
Deleuze, Jean-François
Lucchesi, Carlo
Mathoulin-Pelissier, Simone
Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
title Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
title_full Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
title_fullStr Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
title_full_unstemmed Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
title_short Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
title_sort molecular profiling of advanced soft-tissue sarcomas: the multisarc randomized trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570026/
https://www.ncbi.nlm.nih.gov/pubmed/34740331
http://dx.doi.org/10.1186/s12885-021-08878-2
work_keys_str_mv AT italianoantoine molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT dinartderek molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT soubeyranisabelle molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT belleracarine molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT esperouhelene molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT delmaschristelle molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT merciernoemie molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT albertsabrina molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT poignieludivine molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT bolandanne molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT bourdonaurelien molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT genestedamien molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT cavaillequentin molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT laizetyechan molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT khalifaemmanuel molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT auzanneauceline molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT squibanbarbara molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT truffauxnathalene molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT olasorobert molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT gerberzuzana molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT walletcedrick molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT benardantoine molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT blayjeanyves molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT laurentpuigpierre molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT deleuzejeanfrancois molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT lucchesicarlo molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT mathoulinpelissiersimone molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial
AT molecularprofilingofadvancedsofttissuesarcomasthemultisarcrandomizedtrial